 |
Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter. |
Palmetto's Initial MDx Pricing Disappoints Industry; Raises Concerns about Business Impact
February 06, 2013
Palmetto's Initial MDx Pricing Disappoints Industry; Raises Concerns about Business Impact
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- CMS Issues Pricing for MDx Codes; Labs, Test Developers Still Critical of Rates and Methodology
May 22, 2013 / Pharmacogenomics Reporter - Study Finds KRAS Testing in Metastatic CRC Saves Money, but Questions Value of EGFR Inhibitors
November 28, 2012 / Pharmacogenomics Reporter - Roche Receives FDA Nod for New PGx Indication for Tarceva in Metastatic NSCLC with Companion Dx
May 15, 2013 / Pharmacogenomics Reporter - Pharmas and Dx Partners Race to Launch the First Personalized EGFR Inhibitor for Lung Cancer
January 16, 2013 / Pharmacogenomics Reporter - Qiagen's Experience Developing KRAS CDx for Erbitux Yields Lessons for Rx/Dx Development
November 28, 2012 / Pharmacogenomics Reporter